pmid	doi	year	title	Hugo_Symbol
34319003	10.1002/cnr2.1524	2022	Serum proteome modulations upon treatment provides biological insight on response to treatment in relapsed mantle cell lymphoma.	BTK
34332791	10.1016/j.pathol.2021.04.008	2022	Morphologic and molecular analysis of Richter syndrome in chronic lymphocytic leukaemia patients treated with ibrutinib or venetoclax.	BTK
34615723	10.1158/1078-0432.CCR-21-2183	2022	Phase I/Ib Study of the Efficacy and Safety of Buparlisib and Ibrutinib Therapy in MCL, FL, and DLBCL with Serial Cell-Free DNA Monitoring.	BTK
34638136	10.1182/bloodadvances.2020003698	2022	Zanubrutinib monotherapy for relapsed or refractory non-germinal center diffuse large B-cell lymphoma.	BTK
34679161	10.1182/blood.2021013326	2022	Therapeutic options for relapsed/refractory mantle cell lymphoma.	BTK
34713475	10.1002/hon.2943	2022	Treatment strategies for a rapidly evolving landscape in chronic lymphocytic leukemia management.	BTK
34714908	10.1182/bloodadvances.2021005486	2022	Integrative genomic and transcriptomic analysis in plasmablastic lymphoma identifies disruption of key regulatory pathways.	BTK
34724705	10.1182/bloodadvances.2021005621	2022	Pooled safety analysis of zanubrutinib monotherapy in patients with B-cell malignancies.	BTK
34783281	10.1080/10428194.2021.1999444	2022	Targeting MALT1 for the treatment of diffuse large B-cell lymphoma.	BTK
34795418	10.1038/s41375-021-01470-4	2022	Inhibitors of Bcl-2 and Bruton's tyrosine kinase synergize to abrogate diffuse large B-cell lymphoma growth in vitro and in orthotopic xenotransplantation models.	BTK
34817087	10.1002/hon.2952	2022	Outcome of patients with mantle cell lymphoma after autologous stem cell transplantation in the pre-CAR T-cell era.	BTK
34821081	10.1002/cnr2.1590	2022	Mantle cell lymphoma: A clinical review of the changing treatment paradigms with the advent of novel therapies, and an insight into Indian data.	BTK
34839996	10.1016/j.ejmech.2021.114009	2022	Review of the development of BTK inhibitors in overcoming the clinical limitations of ibrutinib.	BTK
34843717	10.1016/j.bcp.2021.114861	2022	Luxeptinib disables NLRP3 inflammasome-mediated IL-1β release and pathways required for secretion of inflammatory cytokines IL-6 and TNFα.	BTK
34861036	10.1182/blood.2021014085	2022	Efficacy of a third BNT162b2 mRNA COVID-19 vaccine dose in patients with CLL who failed standard 2-dose vaccination.	BTK
34861696	10.1182/bloodadvances.2021006211	2022	Single-cell sequencing demonstrates complex resistance landscape in CLL and MCL treated with BTK and BCL2 inhibitors.	BTK
34905129	10.1007/s11523-021-00857-8	2022	Bruton Tyrosine Kinase Inhibitors in B-Cell Malignancies: Their Use and Differential Features.	BTK
34910982	10.1016/j.bioorg.2021.105541	2022	Discovery of pyrido[3,4-b]indol-1-one derivatives as novel non-covalent Bruton's tyrosine kinase (BTK) inhibitors.	BTK
34932207	10.1007/s40265-021-01657-0	2022	Current Treatment of Chronic Lymphocytic Leukemia: The Diminishing Role of Chemoimmunotherapy.	BTK
35031886	10.1186/s43556-021-00066-9	2022	Combinatorial inhibition of BTK, PI3K-AKT and BRD4-MYC as a strategy for treatment of mantle cell lymphoma.	BTK
35068379	10.1080/16078454.2021.2019363	2022	Application of new targeted drugs in relapsed/refractory primary central nervous system lymphoma.	BTK
35076567	10.3390/neurolint14010009	2022	Ibrutinib in Refractory or Relapsing Primary Central Nervous System Lymphoma: A Systematic Review.	BTK
35078814	10.1158/0008-5472.CAN-21-0218	2022	Targeting Cellular Iron Homeostasis with Ironomycin in Diffuse Large B-cell Lymphoma.	BTK
35096069	10.1155/2022/1182384	2022	Utility of Bruton's Tyrosine Kinase Inhibitors in Light Chain Amyloidosis Caused by Lymphoplasmacytic Lymphoma (Waldenström's Macroglobulinemia).	BTK
35115740	10.1007/s12288-021-01433-w	2022	Ibrutinib in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Retrospective Study.	BTK
35123927	10.1016/j.clml.2022.01.008	2022	SOHO State of the Art Updates and Next Questions: Managing Relapsed Mantle Cell Lymphoma.	BTK
35139644	10.2217/fon-2021-0602	2022	Acalabrutinib and its use in the treatment of chronic lymphocytic leukemia.	BTK
35149375	10.1016/j.ctarc.2022.100527	2022	Current approach to Waldenström Macroglobulinemia.	BTK
35169086	10.11477/mf.1436204531	2022	[Perspectives on Precision Medicine in Primary Central Nervous System Lymphoma].	BTK
35184664	10.1080/17474086.2022.2044778	2022	Management of relapsed or refractory large B-cell lymphoma in patients ineligible for CAR-T cell therapy.	BTK
35188143	10.1358/dot.2022.58.2.3360405	2022	Research progress in overcoming ibrutinib drug resistance.	BTK
35205606	10.3390/cancers14040860	2022	Regulation of B-Cell Receptor Signaling and Its Therapeutic Relevance in Aggressive B-Cell Lymphomas.	BTK
35230873	10.1126/scisignal.abk3083	2022	Phosphorylation of serine-893 in CARD11 suppresses the formation and activity of the CARD11-BCL10-MALT1 complex in T and B cells.	BTK
35237395	10.1177/20406207221080738	2022	Chimeric antigen receptor (CAR) T-cell treatment for mantle cell lymphoma (MCL).	BTK
35247223	10.1002/hon.2983	2022	Use of BTK inhibitors with focus on ibrutinib in mantle cell lymphoma: An expert panel opinion statement.	BTK
35247800	10.1016/j.thromres.2022.02.020	2022	The effect of Bruton's tyrosine kinase inhibitor ibrutinib on atherothrombus formation under stenotic flow conditions.	BTK
35255496	10.1182/bloodadvances.2021006147	2022	A new role for the SRC family kinase HCK as a driver of SYK activation in MYD88 mutated lymphomas.	BTK
35266562	10.1002/ajh.26523	2022	Mantle cell lymphoma in 2022-A comprehensive update on molecular pathogenesis, risk stratification, clinical approach, and current and novel treatments.	BTK
35273899	10.1055/s-0042-1744128	2022	Spontaneous Spinal Subdural Hematoma Secondary to Hemophilia A and Zanubrutinib.	BTK
35294723	10.1007/s11864-022-00973-1	2022	Novel Approaches for the Treatment of Patients with Richter's Syndrome.	BTK
35296646	10.1038/s41419-022-04684-1	2022	Dual BTK/SYK inhibition with CG-806 (luxeptinib) disrupts B-cell receptor and Bcl-2 signaling networks in mantle cell lymphoma.	BTK
35303070	10.1182/blood.2021014162	2022	Zanubrutinib in relapsed/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study.	BTK
35306137	10.1016/j.cellsig.2022.110311	2022	B-cell receptor signaling induces proteasomal degradation of PDCD4 via MEK1/2 and mTORC1 in malignant B cells.	BTK
35306909	10.1177/10781552221087730	2022	A fatal disseminated cryptococcal infection in a patient treated with zanubrutinib for Waldenström's macroglobulinemia.	BTK
35326604	10.3390/cancers14061453	2022	DLBCL 1L-What to Expect beyond R-CHOP?	BTK
35330376	10.3390/jpm12030376	2022	Relapsed/Refractory Mantle Cell Lymphoma: Beyond BTK Inhibitors.	BTK
35339405	10.1016/j.clml.2022.02.005	2022	SOHO State of the Art Updates and Next Questions: Targeted therapies and emerging novel treatment approaches for Waldenström Macroglobulinemia.	BTK
35350909	10.1177/10781552221090869	2022	Real-world management of targeted therapies in chronic lymphocytic leukemia.	BTK
35379357	10.1186/s40364-022-00357-5	2022	Combining BTK inhibitors with BCL2 inhibitors for treating chronic lymphocytic leukemia and mantle cell lymphoma.	BTK
35403972	10.1007/s11912-022-01250-y	2022	Targeting The Tumor Microenvironment in Lymphomas: Emerging Biological Insights and Therapeutic Strategies.	BTK
35411248	NA	2022	PIK-75 overcomes venetoclax resistance <i>via</i> blocking PI3K-AKT signaling and MCL-1 expression in mantle cell lymphoma.	BTK
35411950	10.1002/cbf.3702	2022	USP7 sustains an active epigenetic program via stabilizing MLL2 and WDR5 in diffuse large B-cell lymphoma.	BTK
35435617	10.1007/s11864-022-00953-5	2022	Chronic Lymphocytic Leukemia: Chemotherapy Free and Other Novel Therapies Including CAR T.	BTK
35440579	10.1038/s41467-022-29835-y	2022	A loss-of-adhesion CRISPR-Cas9 screening platform to identify cell adhesion-regulatory proteins and signaling pathways.	BTK
35450208	10.1177/20406207221090886	2022	Updates in hairy cell leukemia (HCL) and variant-type HCL (HCL-V): rationale for targeted treatments with a focus on ibrutinib.	BTK
35482146	10.1007/s11307-022-01733-1	2022	[<sup>18</sup>F]BTK-1: A Novel Positron Emission Tomography Tracer for Imaging Bruton's Tyrosine Kinase.	BTK
35510210	10.1177/20406207221093962	2022	Treatment paradigm in Waldenström macroglobulinemia: frontline therapy and beyond.	BTK
35558005	10.1177/17588359221093745	2022	Novel insights into the biomarkers and therapies for primary central nervous system lymphoma.	BTK
35561314	10.1182/bloodadvances.2022007247	2022	Evaluating real-world treatment patterns and outcomes of mantle cell lymphoma.	BTK
35571529	10.1155/2022/1930546	2022	Ibrutinib Plus R-ICE Induces Remission in Blastoid Variant Mantle Cell Lymphoma with CNS Relapse.	BTK
35577753	10.1016/j.clml.2022.04.017	2022	SOHO State of the Art Updates and Next Questions | Management of Most Difficult Cases of Chronic Lymphocytic Leukemia: Relapse After Both BTK and BCL2 Inhibition and Richter Transformation.	BTK
35596920	10.1007/s11912-022-01286-0	2022	BTK Inhibitors and CAR T-Cell Therapy in Treating Mantle Cell Lymphoma-Finding a Dancing Partner.	BTK
35597428	10.1016/j.cellsig.2022.110358	2022	BTK-independent regulation of calcium signalling downstream of the B-cell receptor in malignant B-cells.	BTK
35628381	10.3390/ijms23105570	2022	<i>MYD88</i> Mutations: Transforming the Landscape of IgM Monoclonal Gammopathies.	BTK
35639332	10.1007/s11912-022-01297-x	2022	Mantle Cell Lymphoma: the Role of Risk-Adapted Therapy and Treatment of Relapsed Disease.	BTK
35651781	10.1177/20406207221093980	2022	Zanubrutinib in lymphoproliferative disorders: a comprehensive review.	BTK
35658124	10.1158/2159-8290.CD-21-1566	2022	BCL10 Mutations Define Distinct Dependencies Guiding Precision Therapy for DLBCL.	BTK
35670706	10.1358/dot.2022.58.6.3378055	2022	Brexucabtagene autoleucel: a breakthrough in the treatment of mantle cell lymphoma.	BTK
35671249	10.1021/acs.jmedchem.2c00324	2022	Structural Feature Analyzation Strategies toward Discovery of Orally Bioavailable PROTACs of Bruton's Tyrosine Kinase for the Treatment of Lymphoma.	BTK
35680835	10.19746/j.cnki.issn.1009-2137.2022.03.049	2022	[Clinical Application of Zanubrutinib in B-Cell Lymphoma --Review].	BTK
35714675	10.6004/jnccn.2022.0031	2022	NCCN Guidelines® Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 3.2022.	BTK
35721157	10.3389/fphar.2022.864194	2022	HSP90 Inhibitor Ganetespib Enhances the Sensitivity of Mantle Cell Lymphoma to Bruton's Tyrosine Kinase Inhibitor Ibrutinib.	BTK
35745866	10.3390/pharmaceutics14061294	2022	Design, Synthesis, In Silico Studies and Inhibitory Activity towards Bcr-Abl, BTK and FLT3-ITD of New 2,6,9-Trisubstituted Purine Derivatives as Potential Agents for the Treatment of Leukaemia.	BTK
35757723	10.3389/fimmu.2022.894787	2022	Case Report: Dual Inhibition of HDAC and BTK for Diffuse Large B-Cell Lymphoma After Failure to CD19-Targeted CAR-T Therapy.	BTK
35770040	10.2147/TCRM.S338655	2022	Zanubrutinib in Treating Waldenström Macroglobulinemia, the Last Shall Be the First.	BTK
35785180	10.3389/fonc.2022.901797	2022	Orelabrutinib Combined With Lenalidomide and Immunochemotherapy for Relapsed/Refractory Primary Central Nervous System Lymphoma: A Retrospective Analysis of Case Series.	BTK
35804999	10.3390/cancers14133229	2022	Tumor Microenvironment and Immunotherapy-Based Approaches in Mantle Cell Lymphoma.	BTK
35836543	10.21037/tcr-22-1375	2022	A case report of acquired immunodeficiency syndrome (AIDS)-related refractory Burkitt lymphoma got complete remission by multidisciplinary and multi-target combined therapy.	BTK
35908982	10.1016/j.blre.2022.100992	2022	Follicular lymphoma: The long and winding road leading to your cure?	BTK
35911566	10.2147/BLCTT.S326627	2022	Use of BTK Inhibitors in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): A Practical Guidance.	BTK
35937468	10.6004/jadpro.2022.13.5.14	2022	A Focus on Waldenström Macroglobulinemia and AL Amyloidosis.	BTK
35941532	10.1186/s10020-022-00518-0	2022	Interfering B cell receptor signaling via SHP-1/p-Lyn axis shows therapeutic potential in diffuse large B-cell lymphoma.	BTK
35956064	10.3390/jcm11154447	2022	Bing-Neel Syndrome, a Rare Presentation of Waldenström Macroglobulinemia-A Multicenter Report by the Polish Lymphoma Research Group.	BTK
35957865	10.3389/fonc.2022.941633	2022	Case report: Zanubrutinib-induced dermatological toxicities: A single-center experience and review.	BTK
35973369	10.1016/j.intimp.2022.109138	2022	Zanubrutinib ameliorates lipopolysaccharide-induced acute lung injury via regulating macrophage polarization.	BTK
35975476	10.1002/hon.3056	2022	Ibrutinib combined with low-dose histone deacetylases inhibitor chidamide synergistically enhances the anti-tumor effect in B-cell lymphoma.	BTK
35999205	10.1038/s41408-022-00720-7	2022	Determining drug dose in the era of targeted therapies: playing it (un)safe?	BTK
36029036	10.1111/bjh.18418	2022	Resistance to Bruton tyrosine kinase inhibition in chronic lymphocytic leukaemia and non-Hodgkin lymphoma.	BTK
36029150	10.1002/cpdd.1153	2022	Bioequivalence and Relative Bioavailability Studies to Assess a New Acalabrutinib Formulation That Enables Coadministration With Proton-Pump Inhibitors.	BTK
36035991	10.3389/fcell.2022.935023	2022	Protein Kinase CK2 represents a new target to boost Ibrutinib and Venetoclax induced cytotoxicity in mantle cell lymphoma.	BTK
36051027	10.1002/jha2.489	2022	Inactivating <i>BTK</i> mutations in large B-cell lymphoma in a real-world cohort: Strong correlation with <i>BCL2</i> translocation.	BTK
36051079	10.1002/jha2.428	2022	Targetable alterations in primary extranodal diffuse large B-cell lymphoma.	BTK
36068158	10.1016/j.clml.2022.07.017	2022	Treatment Landscape of Relapsed/Refractory Mantle Cell Lymphoma: An Updated Review.	BTK
36078155	10.3390/cells11172747	2022	Experiences with Glofitamab Administration following CAR T Therapy in Patients with Relapsed Mantle Cell Lymphoma.	BTK
32677095	10.1111/bjh.16946	2021	Ibrutinib for central nervous system lymphoma: the Australasian Lymphoma Alliance/MD Anderson Cancer Center experience.	BTK
32683672	10.1002/ijc.33212	2021	Ibrutinib for improved chimeric antigen receptor T-cell production for chronic lymphocytic leukemia patients.	BTK
32855532	10.1038/s41401-020-00505-3	2021	Activation of unfolded protein response overcomes Ibrutinib resistance in diffuse large B-cell lymphoma.	BTK
32985902	10.2217/fon-2020-0794	2021	A Phase III study of zanubrutinib plus rituximab versus bendamustine plus rituximab in transplant-ineligible, untreated mantle cell lymphoma.	BTK
33011863	10.1007/s00428-020-02937-y	2021	ALK-positive histiocytosis associated with chronic lymphocytic leukaemia/small lymphocytic lymphoma: a multitarget response under ibrutinib.	BTK
33140664	10.1080/10428194.2020.1832660	2021	Phase 2 study of parsaclisib (INCB050465), a highly selective, next-generation PI3Kδ inhibitor, in relapsed or refractory diffuse large B-cell lymphoma (CITADEL-202).	BTK
33216986	10.1111/bjh.17184	2021	Incorporating acalabrutinib, a selective next-generation Bruton tyrosine kinase inhibitor, into clinical practice for the treatment of haematological malignancies.	BTK
33263441	10.1080/17474086.2021.1856652	2021	Development of molecular intervention strategies for B-cell lymphoma.	BTK
33272709	10.1016/j.bioorg.2020.104385	2021	Synthesis and biological activity of imidazole group-substituted arylaminopyrimidines (IAAPs) as potent BTK inhibitors against B-cell lymphoma and AML.	BTK
33288483	10.1016/j.clml.2020.10.015	2021	Primary Central Nervous System Lymphoma: Evolving Biologic Insights and Recent Therapeutic Advances.	BTK
33306268	10.1111/cts.12948	2021	Population Pharmacokinetic Analysis of the BTK Inhibitor Zanubrutinib in Healthy Volunteers and Patients With B-Cell Malignancies.	BTK
33340912	10.1016/j.ejmech.2020.113094	2021	1,4,6-Trisubstituted imidazo[4,5-c]pyridines as inhibitors of Bruton's tyrosine kinase.	BTK
33419778	10.1158/1078-0432.CCR-20-3741	2021	Follicular Lymphoma-associated BTK Mutations are Inactivating Resulting in Augmented AKT Activation.	BTK
33427570	10.1080/10428194.2020.1864352	2021	Acalabrutinib: a highly selective, potent Bruton tyrosine kinase inhibitor for the treatment of chronic lymphocytic leukemia.	BTK
33463471	10.2174/1568026621666210119112336	2021	A Multi-target Drug Designing for BTK, MMP9, Proteasome and TAK1 for the Clinical Treatment of Mantle Cell Lymphoma.	BTK
33552659	10.6004/jadpro.2021.12.1.2	2021	Impact of Adherence to Ibrutinib on Clinical Outcomes in Real-World Patients With Chronic Lymphocytic Leukemia.	BTK
33566715	10.1080/14712598.2021.1889510	2021	Brexucabtagene autoleucel for the treatment of relapsed/refractory mantle cell lymphoma.	BTK
33570649	10.1182/bloodadvances.2020003423	2021	Overcoming resistance to targeted therapies in chronic lymphocytic leukemia.	BTK
33579791	10.1158/1078-0432.CCR-21-0140	2021	A Moving Target: Inactivating BTK Mutations as Drivers of Follicular Lymphoma.	BTK
33629212	10.1007/s12032-021-01470-5	2021	Identification BCL6 and miR-30 family associating with Ibrutinib resistance in activated B-cell-like diffuse large B-cell lymphoma.	BTK
33639170	10.1016/j.jbc.2021.100465	2021	TNF receptor-associated factor 3 restrains B-cell receptor signaling in normal and malignant B cells.	BTK
33645373	10.1080/14740338.2021.1897565	2021	Reducing treatment toxicity in Waldenström macroglobulinemia.	BTK
33676628	10.1016/S0140-6736(21)00224-5	2021	Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study.	BTK
33704654	10.1007/s40265-021-01482-5	2021	Orelabrutinib: First Approval.	BTK
33711241	10.1080/14656566.2021.1902988	2021	Novel synthetic drugs for the treatment of non-Hodgkin lymphoma.	BTK
33718939	10.12703/r/10-22	2021	Managing chronic lymphocytic leukemia in 2020: an update on recent clinical advances with a focus on BTK and BCL-2 inhibitors.	BTK
33730585	10.1016/j.celrep.2021.108870	2021	Transcriptional programming drives Ibrutinib-resistance evolution in mantle cell lymphoma.	BTK
33735664	10.1016/j.neo.2021.02.002	2021	Molecular and genetic biomarkers implemented from next-generation sequencing provide treatment insights in clinical practice for Waldenström macroglobulinemia.	BTK
33740548	10.1016/j.ejmech.2021.113329	2021	Emerging small-molecule inhibitors of the Bruton's tyrosine kinase (BTK): Current development.	BTK
33775465	10.1016/j.blre.2021.100824	2021	Revisiting Richter transformation in the era of novel CLL agents.	BTK
33812443	10.19746/j.cnki.issn.1009-2137.2021.02.052	2021	[New Advances in the Treatment of Primary Central Nervous System Lymphoma--Review].	BTK
33827598	10.1186/s12935-021-01891-2	2021	Down-regulation of cylindromatosis protein phosphorylation by BTK inhibitor promotes apoptosis of non-GCB-diffuse large B-cell lymphoma.	BTK
33851691	10.1358/dot.2021.57.4.3264113	2021	Tirabrutinib hydrochloride for B-cell lymphomas.	BTK
33869054	10.3389/fonc.2021.651057	2021	Role of NFAT in Chronic Lymphocytic Leukemia and Other B-Cell Malignancies.	BTK
33902665	10.1186/s13045-021-01054-w	2021	Current and future treatment strategies in chronic lymphocytic leukemia.	BTK
33902692	10.1186/s40164-021-00222-5	2021	Histological verification of the treatment effect of tirabrutinib for relapsed/refractory primary central nervous system lymphoma.	BTK
33946867	10.3390/cancers13092146	2021	Integration of Metabolomics and Gene Expression Profiling Elucidates IL4I1 as Modulator of Ibrutinib Resistance in ABC-Diffuse Large B Cell Lymphoma.	BTK
33981831	10.1016/j.omto.2021.03.015	2021	Addition of BTK inhibitor orelabrutinib to rituximab improved anti-tumor effects in B cell lymphoma.	BTK
34000704	10.1016/j.bioorg.2021.104968	2021	Design and synthesis of novel substituted benzyl pyrrolopyrimidine derivatives as selective BTK inhibitors for treating mantle cell lymphoma.	BTK
34012272	10.2147/OTT.S300805	2021	Diagnosis and Individualized Treatment of Secondary Central Nervous System Lymphoma: A Case Report.	BTK
34021874	10.1007/s11899-021-00637-1	2021	Frontline Treatment for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Targeted Therapy vs. Chemoimmunotherapy.	BTK
34055635	10.3389/fonc.2021.668162	2021	Acalabrutinib: A Selective Bruton Tyrosine Kinase Inhibitor for the Treatment of B-Cell Malignancies.	BTK
34063667	10.3390/cancers13092198	2021	Targeting BTK Signaling in the Microenvironment of Solid Tumors as a Feasible Cancer Therapy Option.	BTK
34100025	10.1101/2021.06.02.21257804	2021	Impaired Humoral Immunity to SARS-CoV-2 Vaccination in Non-Hodgkin Lymphoma and CLL Patients.	BTK
34108321	10.11406/rinketsu.62.398	2021	[Development and prospects of molecular targeted agents for malignant lymphoma].	BTK
34120550	10.1080/14656566.2021.1941864	2021	Evaluating ibrutinib for the treatment of relapsed/refractory marginal zone lymphoma.	BTK
34123480	10.6004/jadpro.2021.12.4.8	2021	A Review of the Bruton Tyrosine Kinase Inhibitors in B-Cell Malignancies.	BTK
34132782	10.1182/blood.2021011405	2021	The HCK/BTK inhibitor KIN-8194 is active in MYD88-driven lymphomas and overcomes mutated BTKCys481 ibrutinib resistance.	BTK
34137347	10.1080/14740338.2021.1945031	2021	Ibrutinib plus rituximab for the treatment of adult patients with Waldenström's macroglobulinemia: a safety evaluation.	BTK
34159878	10.1080/10428194.2021.1929961	2021	Rationale for once-daily or twice-daily dosing of zanubrutinib in patients with mantle cell lymphoma.	BTK
34170207	10.1080/17474086.2021.1947236	2021	Managing complications secondary to Waldenström's macroglobulinemia.	BTK
34174847	10.1186/s12885-021-08475-3	2021	Distinct BTK inhibitors differentially induce apoptosis but similarly suppress chemotaxis and lipid accumulation in mantle cell lymphoma.	BTK
34177947	10.3389/fimmu.2021.689472	2021	Resistance Mutations to BTK Inhibitors Originate From the NF-κB but Not From the PI3K-RAS-MAPK Arm of the B Cell Receptor Signaling Pathway.	BTK
34185336	10.1002/ajh.26284	2021	BNT162b2 COVID-19 vaccine is significantly less effective in patients with hematologic malignancies.	BTK
34214199	10.1111/ejh.13682	2021	MCIR1: A patient-derived mantle cell lymphoma line for discovering new treatments for ibrutinib resistance.	BTK
34248972	10.3389/fimmu.2021.687458	2021	Targeting Bruton's Tyrosine Kinase in CLL.	BTK
34263144	10.1097/HS9.0000000000000620	2021	The B-cell Receptor Autoantigen LRPAP1 Can Replace Variable Antibody Regions to Target Mantle Cell Lymphoma Cells.	BTK
34264564	10.20892/j.issn.2095-3941.2020.0291	2021	SY-1530, a highly selective BTK inhibitor, effectively treats B-cell malignancies by blocking B-cell activation.	BTK
34269152	10.1080/10428194.2021.1938027	2021	A phase 1/2 study of the combination of acalabrutinib and vistusertib in patients with relapsed/refractory B-cell malignancies.	BTK
34277452	10.3389/fonc.2021.707285	2021	Efficacy and Safety of Ibrutinib in Central Nervous System Lymphoma: A PRISMA-Compliant Single-Arm Meta-Analysis.	BTK
34314938	10.1016/j.bmc.2021.116275	2021	Utilizing structure based drug design and metabolic soft spot identification to optimize the in vitro potency and in vivo pharmacokinetic properties leading to the discovery of novel reversible Bruton's tyrosine kinase inhibitors.	BTK
34320163	10.1182/blood.2020006783	2021	Resistance to Bruton tyrosine kinase inhibitors: the Achilles heel of their success story in lymphoid malignancies.	BTK
34447768	10.3389/fmed.2021.708071	2021	Bruton Tyrosine Kinase Inhibition and Its Role as an Emerging Treatment in Pemphigus.	BTK
34474146	10.1016/j.exphem.2021.08.010	2021	miRNA-223-3p modulates ibrutinib resistance through regulation of the CHUK/Nf-κb signaling pathway in mantle cell lymphoma.	BTK
34478505	10.1182/bloodadvances.2021005083	2021	Outcomes of patients with CLL sequentially resistant to both BCL2 and BTK inhibition.	BTK
34491123	10.1080/17512433.2021.1978288	2021	Clinical pharmacology and PK/PD translation of the second-generation Bruton's tyrosine kinase inhibitor, zanubrutinib.	BTK
34497201	10.11406/rinketsu.62.1139	2021	[Therapeutic algorithm of Waldenström's macroglobulinemia or lymphoplasmacytic lymphoma in Japan].	BTK
34500472	10.1182/bloodadvances.2021004528	2021	Circulating tumor DNA for comprehensive noninvasive monitoring of lymphoma treated with ibrutinib plus nivolumab.	BTK
34508613	10.18632/aging.203314	2021	Bortezomib enhances the anti-cancer effect of the novel Bruton's tyrosine kinase inhibitor (BGB-3111) in mantle cell lymphoma expressing BTK.	BTK
34509879	10.1016/j.ejmech.2021.113820	2021	Discovery of novel BTK PROTACs for B-Cell lymphomas.	BTK
34551904	10.1158/1078-0432.CCR-21-1067	2021	Antitumor Activity of the Novel BTK Inhibitor TG-1701 Is Associated with Disruption of Ikaros Signaling in Patients with B-cell Non-Hodgkin Lymphoma.	BTK
34557659	10.1016/j.isci.2021.102931	2021	The BTK/PI3K/BRD4 axis inhibitor SRX3262 overcomes Ibrutinib resistance in mantle cell lymphoma.	BTK
34606736	10.1080/14728222.2021.1988927	2021	Implications of recent molecular achievements in early diagnosis and precision treatments for primary CNS lymphoma.	BTK
34625994	10.1002/ajh.26367	2021	Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures.	BTK
34651869	10.1002/hon.2933	2021	The resistance mechanisms and treatment strategies of BTK inhibitors in B-cell lymphoma.	BTK
34710755	10.1016/j.phymed.2021.153802	2021	Myricetin exhibit selective anti-lymphoma activity by targeting BTK and is effective via oral administration in vivo.	BTK
34722279	10.3389/fonc.2021.733848	2021	Protein Kinase CK1α Sustains B-Cell Receptor Signaling in Mantle Cell Lymphoma.	BTK
34732441	10.21873/anticanres.15384	2021	Clinicopathologic and Prognostic Significance of Bruton's Tyrosine Kinase Expression in Diffuse Large B-Cell Lymphoma.	BTK
34739844	10.1016/j.ccell.2021.10.006	2021	Effect of ibrutinib with R-CHOP chemotherapy in genetic subtypes of DLBCL.	BTK
34750354	10.1038/s41419-021-04353-9	2021	Cooperative miRNA-dependent PTEN regulation drives resistance to BTK inhibition in B-cell lymphoid malignancies.	BTK
34771535	10.3390/cancers13215372	2021	Update on Novel Therapeutics for Primary CNS Lymphoma.	BTK
34778802	10.1158/2643-3230.BCD-21-0063	2021	Overcoming Acquired Epigenetic Resistance to BTK Inhibitors.	BTK
34858727	10.1080/2162402X.2021.2003533	2021	Tumor cell-derived IL-10 promotes cell-autonomous growth and immune escape in diffuse large B-cell lymphoma.	BTK
34858810	10.3389/fonc.2021.720704	2021	Monitoring and Managing BTK Inhibitor Treatment-Related Adverse Events in Clinical Practice.	BTK
34884478	10.3390/ijms222312673	2021	BTK and PI3K Inhibitors Reveal Synergistic Inhibitory Anti-Tumoral Effects in Canine Diffuse Large B-Cell Lymphoma Cells.	BTK
34970462	10.1155/2021/3964465	2021	Reactivation of <i>Coccidioides immitis</i> in a Prosthetic Knee after Initiation of Chemotherapy.	BTK
34993136	10.3389/fonc.2021.771669	2021	The Determinants of B Cell Receptor Signaling as Prototype Molecular Biomarkers of Leukemia.	BTK
35003920	10.7717/peerj.12571	2021	Inhibition of LINK-A lncRNA overcomes ibrutinib resistance in mantle cell lymphoma by regulating Akt/Bcl2 pathway.	BTK
35087759	10.3389/fonc.2021.801124	2021	Determinants of Drug Resistance in B-Cell Non-Hodgkin Lymphomas: The Case of Lymphoplasmacytic Lymphoma/Waldenström Macroglobulinemia.	BTK
35116520	10.21037/tcr-21-50	2021	Bruton's tyrosine kinase inhibitors in primary central nervous system lymphoma-evaluation of anti-tumor efficacy and brain distribution.	BTK
31316181	10.1038/s41401-019-0250-8	2020	Discovery and biological evaluation of N-(3-(7-((2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-methyl-2-oxo-2H-pyrimido[4,5-d][1,3]oxazin-1(4H)-yl)phenyl)acrylamide as potent Bruton's tyrosine kinase inhibitors.	BTK
31685258	10.1016/j.bioorg.2019.103367	2020	Design and synthesis of novel 1-substituted 3-(6-phenoxypyridin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine analogs as selective BTK inhibitors for the treatment of mantle cell lymphoma.	BTK
31699386	10.1016/j.bioorg.2019.103361	2020	New 2,6,9-trisubstituted purine derivatives as Bcr-Abl and Btk inhibitors and as promising agents against leukemia.	BTK
31699465	10.1016/j.blre.2019.100635	2020	Immunomodulatory effect of ibrutinib: Reducing the barrier against fungal infections.	BTK
31738609	10.1080/14656566.2019.1689959	2020	An in-depth evaluation of acalabrutinib for the treatment of mantle-cell lymphoma.	BTK
31772331	10.1038/s41388-019-1122-x	2020	Potent efficacy of MCL-1 inhibitor-based therapies in preclinical models of mantle cell lymphoma.	BTK
31782972	10.1002/hon.2694	2020	New responsibilities for aged kinases in B-lymphomas.	BTK
31831562	10.1158/1078-0432.CCR-19-2202	2020	Preclinical Evaluation of a Novel SHIP1 Phosphatase Activator for Inhibition of PI3K Signaling in Malignant B Cells.	BTK
31862225	10.1016/j.jocn.2019.11.013	2020	Bing-Neel syndrome presenting as isolated CNS lymphoplasmacytic lymphoma: A case report and review of the literature.	BTK
31865062	10.1016/j.leukres.2019.106286	2020	Naquotinib exerts antitumor activity in activated B-cell-like diffuse large B-cell lymphoma.	BTK
31876911	10.1182/blood.2018884940	2020	Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results.	BTK
31918398	10.1016/j.bioorg.2019.103542	2020	JAK3 inhibitors based on thieno[3,2-d]pyrimidine scaffold: design, synthesis and bioactivity evaluation for the treatment of B-cell lymphoma.	BTK
31931656	10.1080/15384047.2019.1700743	2020	Ibrutinib resistance in a patient with transformed diffuse large B-cell lymphoma from primary pulmonary mucosa-associated lymphoid tissue lymphoma.	BTK
31933167	10.1007/s40265-019-01252-4	2020	Zanubrutinib: First Approval.	BTK
31992103	10.1080/10428194.2020.1719100	2020	A matched case-control study comparing features, treatment and outcomes between patients with non-IgM lymphoplasmacytic lymphoma and Waldenström macroglobulinemia.	BTK
32005797	10.1038/s41408-020-0277-6	2020	SYK is activated by mutated MYD88 and drives pro-survival signaling in MYD88 driven B-cell lymphomas.	BTK
32011729	10.1111/bjh.16416	2020	Efficacy of R-BAC in relapsed, refractory mantle cell lymphoma post BTK inhibitor therapy.	BTK
32014679	10.1016/j.ejmech.2020.112092	2020	Design and synthesis of Imidazo[1,2-b]pyridazine IRAK4 inhibitors for the treatment of mutant MYD88 L265P diffuse large B-cell lymphoma.	BTK
32027299	10.19746/j.cnki.issn.1009-2137.2020.01.056	2020	[Reaserch Advance on Bruton Tyrosine Kinase Inhibitors in the Treatment of B-Cell Tumors--Review].	BTK
32083995	10.1200/JCO.19.02314	2020	Genomic Landscape of Waldenström Macroglobulinemia and Its Impact on Treatment Strategies.	BTK
32093809	10.3727/096504020X15825405463920	2020	A Novel BCL-2 Inhibitor APG-2575 Exerts Synthetic Lethality With BTK or MDM2-p53 Inhibitor in Diffuse Large B-Cell Lymphoma.	BTK
32127472	10.1073/pnas.1921187117	2020	Regulation of B cell receptor-dependent NF-κB signaling by the tumor suppressor KLHL14.	BTK
32127939	10.7150/jca.34981	2020	Apigenin and Abivertinib, a novel BTK inhibitor synergize to inhibit diffuse large B-cell lymphoma <i>in vivo and vitro</i>.	BTK
32162560	10.1080/14656566.2020.1737010	2020	Approved and emerging PI3K inhibitors for the treatment of chronic lymphocytic leukemia and non-Hodgkin lymphoma.	BTK
32186759	10.3892/mmr.2020.11022	2020	PDGFD induces ibrutinib resistance of diffuse large B‑cell lymphoma through activation of EGFR.	BTK
32207333	10.2217/fon-2019-0844	2020	ALPINE: zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.	BTK
32209572	10.1158/1078-0432.CCR-19-2856	2020	Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study.	BTK
32239765	10.1002/ajh.25796	2020	Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (MCL) - outcomes and mutation profile from venetoclax resistant MCL patients.	BTK
32242358	10.1056/NEJMoa1914347	2020	KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma.	BTK
32253666	10.1007/s12185-020-02867-0	2020	Evolution in the management of chronic lymphocytic leukemia in Japan: should MRD negativity be the goal?	BTK
32292084	10.1080/14656566.2020.1751123	2020	Duvelisib for the treatment of chronic lymphocytic leukemia.	BTK
32321318	10.1080/13543784.2020.1760245	2020	Novel agents for mantle cell lymphoma: molecular rational and clinical data.	BTK
32333154	10.1007/s00277-020-04005-6	2020	A phase II study of ibrutinib in combination with rituximab-cyclophosphamide-doxorubicin hydrochloride-vincristine sulfate-prednisone therapy in Epstein-Barr virus-positive, diffuse large B cell lymphoma (54179060LYM2003: IVORY study): results of the final analysis.	BTK
32370190	10.3390/cancers12051143	2020	Differential B-Cell Receptor Signaling Requirement for Adhesion of Mantle Cell Lymphoma Cells to Stromal Cells.	BTK
32382949	10.1007/s40265-020-01318-8	2020	Tirabrutinib: First Approval.	BTK
32393328	10.1186/s13045-020-00884-4	2020	Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with the BTK inhibitor zanubrutinib: phase 2, single-arm, multicenter study.	BTK
32400331	10.2174/1389557520666200513121524	2020	Irreversible Kinase Inhibitors Targeting Cysteine Residues and their Applications in Cancer Therapy.	BTK
32420699	10.1002/cam4.3136	2020	Serine-227 in the N-terminal kinase domain of RSK2 is a potential therapeutic target for mantle cell lymphoma.	BTK
32455989	10.3390/cancers12051328	2020	Ibrutinib Resistance Mechanisms and Treatment Strategies for B-Cell lymphomas.	BTK
32461234	10.1158/1078-0432.CCR-19-3703	2020	Treatment of Patients with Relapsed or Refractory Mantle-Cell Lymphoma with Zanubrutinib, a Selective Inhibitor of Bruton's Tyrosine Kinase.	BTK
32481736	10.3390/cancers12061396	2020	Mechanisms of B Cell Receptor Activation and Responses to B Cell Receptor Inhibitors in B Cell Malignancies.	BTK
32484067	10.1177/1091581820918511	2020	Nonclinical Safety Assessment of Zanubrutinib: A Novel Irreversible BTK Inhibitor.	BTK
32519423	10.1002/1878-0261.12742	2020	Abivertinib synergistically strengthens the anti-leukemia activity of venetoclax in acute myeloid leukemia in a BTK-dependent manner.	BTK
32552760	10.1186/s13045-020-00914-1	2020	Emerging therapies in mantle cell lymphoma.	BTK
32563910	10.1016/j.tranon.2020.100817	2020	Ibrutinib is not an effective drug in primografts of TCF3-PBX1.	BTK
32582577	10.2147/ITT.S240874	2020	Bruton's Tyrosine Kinase Inhibitors: A New Therapeutic Target for the Treatment of SLE?	BTK
32585766	10.1002/1878-0261.12753	2020	Identification of BLNK and BTK as mediators of rituximab-induced programmed cell death by CRISPR screens in GCB-subtype diffuse large B-cell lymphoma.	BTK
32586008	10.3390/biomedicines8060170	2020	ROR1 Is Expressed in Diffuse Large B-Cell Lymphoma (DLBCL) and a Small Molecule Inhibitor of ROR1 (KAN0441571C) Induced Apoptosis of Lymphoma Cells.	BTK
32598477	10.1182/bloodadvances.2019001350	2020	Genetic mutations and features of mantle cell lymphoma: a systematic review and meta-analysis.	BTK
32603202	10.1080/14656566.2020.1770727	2020	An evaluation of Ibrutinib for the treatment of Waldenstrom macroglobulinaemia.	BTK
32613545	10.1007/s40257-020-00535-x	2020	Dermatological Toxicities of Bruton's Tyrosine Kinase Inhibitors.	BTK
32631091	10.1080/14737140.2020.1791705	2020	The current role of BTK inhibitors in the treatment of Waldenstrom's Macroglobulinemia.	BTK
32643971	10.1177/0300060520936053	2020	Chidamide combined with ibrutinib improved the prognosis of primary bone marrow diffuse large B cell lymphoma.	BTK
32644193	10.1002/cncr.33058	2020	US Food and Drug Administration approvals for Bruton tyrosine kinase inhibitors in patients with chronic lymphocytic leukemia: Potential inefficiencies in trial design and evidence generation.	BTK
32691208	10.1007/s11060-020-03580-y	2020	Repolarization of tumor infiltrating macrophages and increased survival in mouse primary CNS lymphomas after XPO1 and BTK inhibition.	BTK
32715803	10.1080/14740338.2020.1802424	2020	Safety considerations with targeted therapy drugs for B-cell non-Hodgkin lymphoma.	BTK
32753893	10.2147/OTT.S238832	2020	Evaluating the Therapeutic Potential of Zanubrutinib in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma: Evidence to Date.	BTK
32824276	10.3390/cancers12082303	2020	Macrophage-Mediated Antibody Dependent Effector Function in Aggressive B-Cell Lymphoma Treatment is Enhanced by Ibrutinib via Inhibition of JAK2.	BTK
32861286	10.1016/j.hoc.2020.06.007	2020	Current Role and Emerging Evidence for Bruton Tyrosine Kinase Inhibitors in the Treatment of Mantle Cell Lymphoma.	BTK
32861287	10.1016/j.hoc.2020.06.008	2020	What Causes Bruton Tyrosine Kinase Inhibitor Resistance in Mantle Cell Lymphoma and How Should We Treat Such Patients?	BTK
32861288	10.1016/j.hoc.2020.06.009	2020	Blastoid Mantle Cell Lymphoma.	BTK
32864130	10.1186/s40364-020-00214-3	2020	A genetic predictive model for precision treatment of diffuse large B-cell lymphoma with early progression.	BTK
32869675	10.1080/17474086.2020.1817735	2020	An evaluation of zanubrutinib, a BTK inhibitor, for the treatment of chronic lymphocytic leukemia.	BTK
32899476	10.3390/cancers12092525	2020	Relevant Cytokines in the B Cell Lymphoma Micro-Environment.	BTK
32926124	10.1182/bloodadvances.2020001685	2020	Targeting phosphatidylinositol 3 kinase-β and -δ for Bruton tyrosine kinase resistance in diffuse large B-cell lymphoma.	BTK
32955949	10.1080/14728214.2020.1822816	2020	Emerging drugs for the treatment of Waldenström macroglobulinemia.	BTK
33005100	10.1186/s12935-020-01518-y	2020	Ibrutinib in B-cell lymphoma: single fighter might be enough?	BTK
33020271	10.1073/pnas.2007946117	2020	Rewiring of B cell receptor signaling by Epstein-Barr virus LMP2A.	BTK
33025948	10.1358/dot.2020.56.8.3158047	2020	Zanubrutinib: a new BTK inhibitor for treatment of relapsed/refractory mantle cell lymphoma.	BTK
33068336	10.1002/cam4.3499	2020	Clinical outcomes of newly diagnosed primary CNS lymphoma treated with ibrutinib-based combination therapy: A real-world experience of off-label ibrutinib use.	BTK
33091356	10.1016/S2352-3026(20)30224-6	2020	Consensus treatment recommendations from the tenth International Workshop for Waldenström Macroglobulinaemia.	BTK
33091668	10.1016/j.bioorg.2020.104377	2020	HZ-A-005, a potent, selective, and covalent Bruton's tyrosine kinase inhibitor in preclinical development.	BTK
33091850	10.1016/j.bmc.2020.115815	2020	Improving metabolic stability and removing aldehyde oxidase liability in a 5-azaquinazoline series of IRAK4 inhibitors.	BTK
33093947	10.12688/f1000research.22318.1	2020	ACCEPT - combining acalabrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) for Diffuse Large B-cell Lymphoma (DLBCL): study protocol for a Phase Ib/II open-label non-randomised clinical trial.	BTK
33109547	10.21873/anticanres.14630	2020	Inhibition of Bruton's Tyrosine Kinase Suppresses Cancer Stemness and Promotes Carboplatin-induced Cytotoxicity Against Bladder Cancer Cells.	BTK
33154951	10.3389/fonc.2020.591577	2020	Genetic and Non-Genetic Mechanisms of Resistance to BCR Signaling Inhibitors in B Cell Malignancies.	BTK
33188997	10.1016/j.ctarc.2020.100235	2020	Activity of ibrutinib plus R-CHOP in diffuse large B-cell lymphoma: Response, pharmacodynamic, and biomarker analyses of a phase Ib study.	BTK
33214835	10.1021/acsmedchemlett.0c00378	2020	Discovery of a Selective, Covalent IRAK1 Inhibitor with Antiproliferative Activity in MYD88 Mutated B-Cell Lymphoma.	BTK
33226337	10.7554/eLife.60470	2020	Differential impact of BTK active site inhibitors on the conformational state of full-length BTK.	BTK
33273169	10.1212/CON.0000000000000936	2020	Central Nervous System Lymphomas.	BTK
33275726	10.1182/hematology.2020000121	2020	Management of Waldenström macroglobulinemia in 2020.	BTK
33489445	NA	2020	Ibrutinib in association with venetoclax for the treatment of mantle-cell lymphoma: a multicenter case series.	BTK
34667996	10.21037/aol-20-20	2020	Targeting pathogenic mechanisms in marginal zone lymphoma: from concepts and beyond.	BTK
35117332	10.21037/tcr-20-72	2020	Additional possibilities of chimeric antigen receptor T-cells in B-cell lymphoma: combination therapy.	BTK
30381956	10.2217/fon-2018-0637	2019	Acalabrutinib and its use in treatment of chronic lymphocytic leukemia.	BTK
30413649	10.1158/1535-7163.MCT-18-0478	2019	Pleiotropic Action of Novel Bruton's Tyrosine Kinase Inhibitor BGB-3111 in Mantle Cell Lymphoma.	BTK
30423172	10.1093/neuonc/noy193	2019	Introduction of novel agents in the treatment of primary CNS lymphoma.	BTK
30453157	10.1016/j.jpba.2018.11.012	2019	Novel Bruton tyrosine kinase inhibitor acalabrutinib quantification by validated LC-MS/MS method: An application to pharmacokinetic study in Sprague Dawley rats.	BTK
30522954	10.1016/j.bmcl.2018.11.051	2019	Synthesis and biological evaluation of novel 1-substituted 3-(3-phenoxyprop-1-yn-1-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amines as potent Bruton's tyrosine kinase (BTK) inhibitors.	BTK
30545835	10.1182/blood-2018-07-862953	2019	Bruton tyrosine kinase degradation as a therapeutic strategy for cancer.	BTK
30546948	10.1080/2162402X.2018.1512455	2019	Ibrutinib significantly inhibited Bruton's tyrosine kinase (BTK) phosphorylation,<i>in-vitro</i> proliferation and enhanced overall survival in a preclinical Burkitt lymphoma (BL) model.	BTK
30556110	10.1007/s40262-018-0725-7	2019	Population Pharmacokinetics of the BTK Inhibitor Acalabrutinib and its Active Metabolite in Healthy Volunteers and Patients with B-Cell Malignancies.	BTK
30567753	10.1182/blood-2018-09-875732	2019	Phase 1b trial of an ibrutinib-based combination therapy in recurrent/refractory CNS lymphoma.	BTK
30638402	10.1080/17512433.2019.1568868	2019	Acalabrutinib for adults with mantle cell lymphoma.	BTK
30692121	10.1182/blood-2018-11-886457	2019	A phase 1 trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma.	BTK
30693983	10.1002/mc.22983	2019	The HDAC6-selective inhibitor is effective against non-Hodgkin lymphoma and synergizes with ibrutinib in follicular lymphoma.	BTK
30700840	10.1038/s41375-018-0366-8	2019	New roles for B cell receptor associated kinases: when the B cell is not the target.	BTK
30719267	10.1177/2040620718820510	2019	Novel treatment approaches and future perspectives in follicular lymphoma.	BTK
30723172	10.1126/scisignal.aat4105	2019	Interrogating B cell signaling pathways: A quest for novel therapies for mantle cell lymphoma.	BTK
30777096	10.1186/s13046-019-1076-4	2019	Combination of Enzastaurin and Ibrutinib synergistically induces anti-tumor effects in diffuse large B cell lymphoma.	BTK
30791947	10.1186/s40425-019-0529-9	2019	A good response of refractory mantel cell lymphoma to haploidentical CAR T cell therapy after failure of autologous CAR T cell therapy.	BTK
30821551	10.1080/10428194.2019.1569231	2019	Modulation of immune checkpoint molecule expression in mantle cell lymphoma.	BTK
30857748	10.1016/j.bmcl.2019.03.005	2019	Discovery of novel pyrazole derivatives as potential anticancer agents in MCL.	BTK
30862686	10.1158/1541-7786.MCR-18-0256	2019	Metabolic Detection of Bruton's Tyrosine Kinase Inhibition in Mantle Cell Lymphoma Cells.	BTK
30872780	10.1038/s41375-019-0442-8	2019	Inhibition of SYK or BTK augments venetoclax sensitivity in SHP1-negative/BCL-2-positive diffuse large B-cell lymphoma.	BTK
30875504	10.1016/j.ejmech.2019.02.077	2019	Design, synthesis and evaluation of novel 7H-pyrrolo[2,3-d]pyrimidin-4-amine derivatives as potent, selective and reversible Bruton's tyrosine kinase (BTK) inhibitors for the treatment of rheumatoid arthritis.	BTK
30878129	10.1016/j.critrevonc.2019.02.001	2019	Management of adverse effects/toxicity of ibrutinib.	BTK
30884247	10.1080/17474086.2019.1596793	2019	Novel agents may positively impact chemotherapy and transplantation in subsets of diffuse large B-cell lymphoma.	BTK
30887112	10.1007/s00109-019-01777-x	2019	Activation of NF-κB in B cell receptor signaling through Bruton's tyrosine kinase-dependent phosphorylation of IκB-α.	BTK
30888232	10.1080/13543776.2019.1594777	2019	Bruton's tyrosine kinase (BTK) inhibitors in treating cancer: a patent review (2010-2018).	BTK
30907011	10.1002/cbf.3381	2019	TAK1 is a druggable kinase for diffuse large B-cell lymphoma.	BTK
30916599	10.1080/17474086.2019.1597703	2019	Ibrutinib for the treatment of chronic lymphocytic leukemia.	BTK
30927175	10.1007/s11523-019-00635-7	2019	Inhibiting Bruton's Tyrosine Kinase in CLL and Other B-Cell Malignancies.	BTK
30940906	10.1038/s41375-019-0463-3	2019	CSF1R and BTK inhibitions as novel strategies to disrupt the dialog between mantle cell lymphoma and macrophages.	BTK
30963600	10.1002/ajh.25487	2019	Mantle cell lymphoma: 2019 update on the diagnosis, pathogenesis, prognostication, and management.	BTK
30999237	10.1016/j.ejmech.2019.03.055	2019	Discovery of 7H-pyrrolo[2,3-d]pyrimidine derivatives as selective covalent irreversible inhibitors of interleukin-2-inducible T-cell kinase (Itk).	BTK
31031018	10.1016/j.bioorg.2019.102943	2019	Discovery of pyrazolopyrimidine derivatives as potent BTK inhibitors with effective anticancer activity in MCL.	BTK
31043832	10.3747/co.26.4345	2019	Review of Bruton tyrosine kinase inhibitors for the treatment of relapsed or refractory mantle cell lymphoma.	BTK
31109313	10.1186/s12885-019-5717-y	2019	The STELLAR trial protocol: a prospective multicentre trial for Richter's syndrome consisting of a randomised trial investigation CHOP-R with or without acalabrutinib for newly diagnosed RS and a single-arm platform study for evaluation of novel agents in relapsed disease.	BTK
31123343	10.1038/s41375-019-0489-6	2019	PRMT5 is upregulated by B-cell receptor signaling and forms a positive-feedback loop with PI3K/AKT in lymphoma cells.	BTK
31187531	10.1002/hon.2596	2019	The modern approach to mantle cell lymphoma.	BTK
31188814	NA	2019	Bruton tyrosine kinase inhibitors for the treatment of mantle cell lymphoma: review of current evidence and future directions.	BTK
31189540	10.1136/jclinpath-2019-205837	2019	Diffuse large B-cell lymphoma in Southeast Asian cohort: expression patterns of B-cell receptor (BCR) repertoire and its linkage with molecular subtypes and response to R-CHOP therapy.	BTK
31217352	10.1172/jci.insight.127566	2019	Noncovalent inhibitors reveal BTK gatekeeper and auto-inhibitory residues that control its transforming activity.	BTK
31229160	10.1016/j.hoc.2019.03.004	2019	Lymphoplasmacytic Lymphoma and Marginal Zone Lymphoma.	BTK
31233483	10.1097/CCO.0000000000000556	2019	Mantle cell lymphoma in patients not eligible for autologous stem cell transplantation.	BTK
31286638	10.1111/vco.12520	2019	Effects of ibrutinib on proliferation and histamine release in canine neoplastic mast cells.	BTK
31296529	10.1158/1078-0432.CCR-19-0273	2019	Eμ-TCL1xMyc: A Novel Mouse Model for Concurrent CLL and B-Cell Lymphoma.	BTK
31340982	10.1182/blood.2019001160	2019	Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL.	BTK
31355927	10.1111/bjh.16118	2019	Single and combined BTK and PI3Kδ inhibition with acalabrutinib and ACP-319 in pre-clinical models of aggressive lymphomas.	BTK
31364164	10.1111/bph.14809	2019	A non-covalent inhibitor XMU-MP-3 overrides ibrutinib-resistant Btk<sup>C481S</sup> mutation in B-cell malignancies.	BTK
31382969	10.1186/s12964-019-0391-x	2019	Pre-clinical blocking of PD-L1 molecule, which expression is down regulated by NF-κB, JAK1/JAK2 and BTK inhibitors, induces regression of activated B-cell lymphoma.	BTK
31384539	10.1016/j.apsb.2019.01.001	2019	Development of the triazole-fused pyrimidine derivatives as highly potent and reversible inhibitors of histone lysine specific demethylase 1 (LSD1/KDM1A).	BTK
31395509	10.1016/j.bmc.2019.07.043	2019	Design, synthesis and biological evaluation of novel dithiocarbamate-substituted diphenylaminopyrimidine derivatives as BTK inhibitors.	BTK
31406628	10.1186/s40164-019-0141-1	2019	Ibrutinib inhibits antibody dependent cellular cytotoxicity induced by rituximab or obinutuzumab in MCL cell lines, not overcome by addition of lenalidomide.	BTK
31420873	10.1002/hon.2667	2019	The impacts of zanubrutinib on immune cells in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.	BTK
31432184	10.3892/or.2019.7282	2019	Disrupting myddosome assembly in diffuse large B‑cell lymphoma cells using the MYD88 dimerization inhibitor ST2825.	BTK
31443360	10.3390/pathogens8030129	2019	Chronic Hepatitis E Virus Infection during Lymphoplasmacytic Lymphoma and Ibrutinib Treatment.	BTK
31481959	10.3389/fimmu.2019.01953	2019	A Novel <i>BTK</i> Gene Mutation in a Child With Atypical X-Linked Agammaglobulinemia and Recurrent Hemophagocytosis: A Case Report.	BTK
31527073	10.1182/blood.2019000725	2019	How I treat Waldenström macroglobulinemia.	BTK
31534006	10.4049/jimmunol.1801327	2019	Cutting Edge: ROR1/CD19 Receptor Complex Promotes Growth of Mantle Cell Lymphoma Cells Independently of the B Cell Receptor-BTK Signaling Pathway.	BTK
31591468	10.1038/s41375-019-0592-8	2019	What is new in the treatment of Waldenstrom macroglobulinemia?	BTK
31619091	10.1080/17474086.2020.1681962	2019	Contemporary management of nodal and primary splenic marginal zone lymphoma.	BTK
31624617	10.1002/ccr3.2257	2019	Complete remission with ibrutinib after allogeneic stem cell transplant for central nervous system relapse of mantle cell lymphoma: A case report and literature review.	BTK
31638169	10.3892/or.2019.7364	2019	Ibrutinib in CLL/SLL: From bench to bedside (Review).	BTK
31648477	10.3760/cma.j.issn.0253-2727.2019.09.008	2019	[Ibrutinib combined with CAR-T cells in the treatment of del (17p) chronic lymphocytic leukemia with BCL-2 inhibitor resistance: a case report and literature review].	BTK
31686856	10.2147/OTT.S155778	2019	Evaluating Acalabrutinib In The Treatment Of Mantle Cell Lymphoma: Design, Development, And Place In Therapy.	BTK
31688198	10.1097/QCO.0000000000000611	2019	Azole antifungals and new targeted therapies for hematological malignancy.	BTK
31708654	10.3747/co.26.4957	2019	Descriptive analysis of dosing and outcomes for patients with ibrutinib-treated relapsed or refractory chronic lymphocytic leukemia in a Canadian centre.	BTK
31723816	10.1097/HS9.0000000000000175	2019	From Biology to Therapy: The CLL Success Story.	BTK
31764119	10.1097/PPO.0000000000000412	2019	Bruton Tyrosine Kinase Inhibitors: Present and Future.	BTK
31766355	10.3390/cancers11121834	2019	Overcoming Ibrutinib Resistance in Chronic Lymphocytic Leukemia.	BTK
31801949	10.1038/s41419-019-2158-0	2019	Resistance to BTK inhibition by ibrutinib can be overcome by preventing FOXO3a nuclear export and PI3K/AKT activation in B-cell lymphoid malignancies.	BTK
31806993	10.2147/OTT.S227122	2019	Genomic Alterations In Primary Cardiac Diffuse Large B Cell Lymphoma: A Case Report And Literature Review.	BTK
31808904	10.1182/hematology.2019001321	2019	Treatment-naive CLL: lessons from phase 2 and phase 3 clinical trials.	BTK
29452660	10.1016/j.beha.2017.10.010	2018	Novel therapies for relapsed/refractory mantle cell lymphoma.	BTK
29455639	10.1186/s12943-018-0779-z	2018	Role of Bruton's tyrosine kinase in B cells and malignancies.	BTK
29472356	10.3324/haematol.2017.184325	2018	A B-cell receptor-related gene signature predicts survival in mantle cell lymphoma: results from the Fondazione Italiana Linfomi MCL-0208 trial.	BTK
29476222	10.1007/s00280-018-3546-3	2018	Ibrutinib brain distribution: a preclinical study.	BTK
29483220	10.1158/1535-7163.MCT-17-0784	2018	p110α Inhibition Overcomes Stromal Cell-Mediated Ibrutinib Resistance in Mantle Cell Lymphoma.	BTK
29483358	10.4049/jimmunol.1701489	2018	Bruton's Tyrosine Kinase Is Not Essential for B Cell Survival beyond Early Developmental Stages.	BTK
29484684	10.1002/hon.2502	2018	Clinical, pathological, and biological characterization of Richter syndrome developing after ibrutinib treatment for relapsed chronic lymphocytic leukemia.	BTK
29496671	10.1182/blood-2017-10-811752	2018	BTK<sup>Cys481Ser</sup> drives ibrutinib resistance via ERK1/2 and protects BTK<sup>wild-type</sup> MYD88-mutated cells by a paracrine mechanism.	BTK
29532266	10.1007/s10753-018-0745-3	2018	Ibrutinib Exacerbates Bleomycin-Induced Pulmonary Fibrosis via Promoting Inflammation.	BTK
29549872	10.1016/j.ctrv.2018.01.002	2018	Targeting the B-cell receptor pathway in diffuse large B-cell lymphoma.	BTK
29560128	10.18632/oncotarget.24310	2018	First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL.	BTK
29567799	10.1182/blood-2017-10-809210	2018	Pan-SRC kinase inhibition blocks B-cell receptor oncogenic signaling in non-Hodgkin lymphoma.	BTK
29590547	10.1056/NEJMoa1715519	2018	Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma.	BTK
29615403	10.1182/blood-2018-02-832535	2018	SOX11 augments BCR signaling to drive MCL-like tumor development.	BTK
29652138	10.1021/acs.bioconjchem.8b00137	2018	Development of a Selective Labeling Probe for Bruton's Tyrosine Kinase Quantification in Live Cells.	BTK
29669753	10.1182/bloodadvances.2017011916	2018	Pilot trial of ibrutinib in patients with relapsed or refractory T-cell lymphoma.	BTK
29690649	10.3390/cancers10040127	2018	Responses to the Selective Bruton's Tyrosine Kinase (BTK) Inhibitor Tirabrutinib (ONO/GS-4059) in Diffuse Large B-cell Lymphoma Cell Lines.	BTK
29712895	10.1038/s41408-018-0076-5	2018	Waldenström macroglobulinemia treatment algorithm 2018.	BTK
29721381	10.1080/2162402X.2017.1423183	2018	FOXO1 promotes resistance of non-Hodgkin lymphomas to anti-CD20-based therapy.	BTK
29725548	10.1155/2018/5471368	2018	A Case Report of Nongerminal Center B-Cell Type Diffuse Large B-Cell Lymphoma Treated to Complete Response with Rituximab and Ibrutinib.	BTK
29735551	10.1158/0008-5472.CAN-17-4004	2018	Novel Richter Syndrome Xenograft Models to Study Genetic Architecture, Biology, and Therapy Responses.	BTK
29737219	10.1080/17474086.2018.1473030	2018	Use of acalabrutinib in patients with mantle cell lymphoma.	BTK
29741794	10.1002/ardp.201700369	2018	Targeting Bruton's tyrosine kinase for the treatment of B cell associated malignancies and autoimmune diseases: Preclinical and clinical developments of small molecule inhibitors.	BTK
29768934	10.1080/14740338.2018.1477936	2018	A safety profile of medications used to treat Waldenström's macroglobulinemia.	BTK
29781323	10.1080/14728214.2018.1479396	2018	Targeting the B-cell receptor pathway: a review of current and future therapies for non-Hodgkin's lymphoma.	BTK
29785709	10.1111/bjh.15411	2018	Four-year follow-up of a single arm, phase II clinical trial of ibrutinib with rituximab (IR) in patients with relapsed/refractory mantle cell lymphoma (MCL).	BTK
29808236	10.1007/s11864-018-0548-7	2018	Pitfalls of Combining Novel Agents in Lymphoma.	BTK
29855199	10.1080/13543784.2018.1482273	2018	Targeting the B cell receptor pathway in non-Hodgkin lymphoma.	BTK
29861875	10.18632/oncotarget.25011	2018	The B cell receptor signaling pathway in mantle cell lymphoma.	BTK
29873072	10.1111/bjh.15421	2018	Evaluation of 230 patients with relapsed/refractory deletion 17p chronic lymphocytic leukaemia treated with ibrutinib from 3 clinical trials.	BTK
29899297	10.3390/ijms19061758	2018	Molecular Mechanisms of Disease Progression in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type during Ibrutinib Therapy.	BTK
29912596	10.1080/10428194.2018.1457148	2018	Understanding resistance mechanisms to BTK and BCL2 inhibitors in mantle cell lymphoma: implications for design of clinical trials.	BTK
29925955	10.1038/s41586-018-0290-0	2018	A multiprotein supercomplex controlling oncogenic signalling in lymphoma.	BTK
30006143	10.1016/j.bmc.2018.07.007	2018	Novel amino acid-substituted diphenylpyrimidine derivatives as potent BTK inhibitors against B cell lymphoma cell lines.	BTK
30011241	10.1177/2472555218786165	2018	Homogeneous BTK Occupancy Assay for Pharmacodynamic Assessment of Tirabrutinib (GS-4059/ONO-4059) Target Engagement.	BTK
30052472	10.1080/17474086.2018.1506327	2018	New and emerging Bruton tyrosine kinase inhibitors for treating mantle cell lymphoma - where do they fit in?	BTK
30069629	10.1007/978-3-319-91439-8_7	2018	Ibrutinib.	BTK
30077608	10.1016/j.bmc.2018.07.047	2018	Design and synthesis of benzofuro[3,2-b]pyridin-2(1H)-one derivatives as anti-leukemia agents by inhibiting Btk and PI3Kδ.	BTK
30104685	10.1038/s41598-018-30509-3	2018	Drug-based perturbation screen uncovers synergistic drug combinations in Burkitt lymphoma.	BTK
30115641	10.1182/bloodadvances.2018016048	2018	Activation of MYC, a bona fide client of HSP90, contributes to intrinsic ibrutinib resistance in mantle cell lymphoma.	BTK
30175400	10.1111/bjh.15567	2018	Long-term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib.	BTK
30190023	10.1016/j.hoc.2018.05.012	2018	First-Generation and Second-Generation Bruton Tyrosine Kinase Inhibitors in Waldenström Macroglobulinemia.	BTK
30209121	10.1182/blood-2018-03-841015	2018	B-cell receptor-mediated NFATc1 activation induces IL-10/STAT3/PD-L1 signaling in diffuse large B-cell lymphoma.	BTK
30231317	10.1200/EDBK_200829	2018	Treatment of Primary Central Nervous System Lymphoma: From Chemotherapy to Small Molecules.	BTK
30280589	10.1080/1062936X.2018.1518927	2018	Molecular modelling studies on cinnoline-based BTK inhibitors using docking and structure-based 3D-QSAR.	BTK
30305939	10.1136/esmoopen-2018-000387	2018	BET bromodomain inhibitor birabresib in mantle cell lymphoma: in vivo activity and identification of novel combinations to overcome adaptive resistance.	BTK
30390220	10.1007/s40265-018-1003-6	2018	Targeting Bruton's Tyrosine Kinase Across B-Cell Malignancies.	BTK
30401751	10.1182/bloodadvances.2018022962	2018	Insights into the genomic landscape of MYD88 wild-type Waldenström macroglobulinemia.	BTK
30510142	10.1158/1535-7163.MCT-17-0789-ATR	2018	XPO1 Inhibitor Selinexor Overcomes Intrinsic Ibrutinib Resistance in Mantle Cell Lymphoma via Nuclear Retention of IκB.	BTK
30534553	10.1155/2018/1042597	2018	Bone Marrow Molecular Markers Associated with Relapsed/Refractory Activated B-Cell-Like Diffuse Large B-Cell Lymphoma.	BTK
28428442	10.1158/1535-7163.MCT-16-0555	2017	Combination of Ibrutinib and ABT-199 in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma.	BTK
26961147	10.1093/annonc/mdw131	2016	Combination of the MEK inhibitor pimasertib with BTK or PI3K-delta inhibitors is active in preclinical models of aggressive lymphomas.	BTK
27157620	10.1038/onc.2016.155	2016	FBXO10 deficiency and BTK activation upregulate BCL2 expression in mantle cell lymphoma.	BTK
25189416	10.1038/leu.2014.263	2015	Functional characterization of BTK(C481S) mutation that confers ibrutinib resistance: exploration of alternative kinase inhibitors.	BTK
25433814	10.1007/s00428-014-1698-z	2015	Bruton's tyrosine kinase (Btk) is a useful marker for Hodgkin and B cell non-Hodgkin lymphoma.	BTK
25944695	10.18632/oncotarget.3824	2015	Irreversible dual inhibitory mode: the novel Btk inhibitor PLS-123 demonstrates promising anti-tumor activity in human B-cell lymphoma.	BTK
26540570	10.18632/oncotarget.6273	2015	Combinatorial BTK and MALT1 inhibition augments killing of CD79 mutant diffuse large B cell lymphoma.	BTK
24658273	10.1038/nrc3702	2014	Targeting Bruton's tyrosine kinase in B cell malignancies.	BTK
24970801	10.18632/oncotarget.2071	2014	Synergistic induction of apoptosis by combination of BTK and dual mTORC1/2 inhibitors in diffuse large B cell lymphoma.	BTK
18241233	10.1111/j.1365-2249.2008.03589.x	2008	Naturally occurring Bruton's tyrosine kinase mutations have no dominant negative effect in an X-linked agammaglobulinaemia cellular model.	BTK
11920564	10.1002/1521-4141(200204)32:4&lt;982::AID-IMMU982&gt;3.0.CO;2-I	2002	Expression profiling in transformed human B cells: influence of Btk mutations and comparison to B cell lymphomas using filter and oligonucleotide arrays.	BTK
8688094	10.1126/science.273.5278.1096	1996	BTK as a mediator of radiation-induced apoptosis in DT-40 lymphoma B cells.	BTK
8283037	NA	1994	Expression of Bruton's agammaglobulinemia tyrosine kinase gene, BTK, is selectively down-regulated in T lymphocytes and plasma cells.	BTK
